Juan Zhou - Publications

Histological Transformation from Non-small Cell Lung Cancer to Small Cell Lung Cancer Induced by Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: September 11, 2025

Taxanes Versus Pemetrexed After Osimertinib Resistance in EGFR-Mutated NSCLC: A Retrospective Cohort with Two-Model In Vitro Validation.

Journal: Cancer management and research

Published: September 03, 2025

Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation.

Journal: Cancer immunology, immunotherapy : CII

Published: June 15, 2025

Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 13, 2022

Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro.

Journal: Cancer management and research

Published: October 02, 2018

Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.

Journal: Oncology reports

Published: June 24, 2017

Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.

Journal: Oncotarget

Published: May 21, 2015

Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.

Journal: PloS one

Published: June 25, 2014

The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.

Journal: Cancer investigation

Published: August 07, 2013